Juno Therapeutics to Resume Drug Study

Juno Therapeutics (JUNO) shares are soaring following news that a study of an experimental treatment for leukemia has been allowed to resume after being modified. The Food and Drug Administration had put a hold on the Phase 2 clinical trial of JCAR015 after two patients died from swelling of the brain. The FDA allowed the trail to continue after Juno said the problem stemmed from a chemotherapy drug used as a pre-treatment step, not from its treatment.